Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 clazosentan study for reversal of cerebral vasospasm after aneurysmal subarachnoid hemorrhage
2015-002721-18Phase 2Terminated
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of clazosentan in cerebral vasospasm and subarachnoid hemorrhage (SAH), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoint: Successful reversal of global cerebral vasospasm at 3 hours. Started Dec 2015; status: terminated.
02
Drugs
clazosentan
03
Conditions
cerebral vasospasmsubarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on 2015-002721-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002721-18.